Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

Shockwave Medical C2+ catheter TCT 2023 announcement

Shockwave Medical introducing more efficient IVL catheter to US market at TCT 2023

According to Shockwave, the updated IVL catheter can deliver 50% more pulses than its previous offering. 

A late-breaking science presentation at the annual TCT interventional cardiology meeting.

Late-breaking clinical trials at TCT 2023

Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.

CVRx Barostim illustration

CVRx, Abbott share long-term heart failure data at THT 2023

CVRx and Abbott used the second annual THT conference as an opportunity to present updated data on their signature heart failure solutions.

Sahil Parikh explains the tread of cardiology departments treating critical limb ischemia (CLI) at AHA 2022.

Interventional cardiology's role in treating CLI continues to evolve

Sahil Parikh, MD, talked to Cardiovascular Business about growing trends related to the treatment of critical lower limb ischemia. "We are getting better and better at saving their limbs, but we are not better at saving their lives," he said. 

a 3D intracardiac echo (ICE) view of a surgical mitral valve using the GE NuVision ICE system.

Can intracardiac echo replace TEE during structural heart procedures?

TEE has been used to guide most transcatheter structural heart cases over the past decade, but 3D ICE is changing how some centers image those patients. 

Ajay J. Kirtane, MD, director of the cardiac catheterization laboratories and professor of medicine at NewYork-Presbyterian/Columbia University Irving Medical Center, explains the current trial data on catheter renal denervation to treat drug-resistant hypertension at AHA 2022.

Where renal denervation stands for the treatment of drug-resistant hypertension

Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic. 

Samir Kapadia, MD, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at Cleveland Clinic, explains why he believes the results of the late-breaking PROTECTED TAVR testing the use of a TAVR cerebral protection device were positive, although it did not meet its primary endpoint.

VIDEO: Exploring the use of cerebral protection devices during TAVR

Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures. 

Juan Granada discusses new cardiac technology AHA22.

VIDEO: 2 key technologies to rapidly advance cardiovascular care

Juan Granada, MD, president and CEO of the Cardiovascular Research Foundation (CRF), shares his thoughts on two key areas of technology advancements in cardiovascular imaging and neuro-interventional care for stroke.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup